Day Zero Diagnostics
Day Zero Diagnostics is a biotechnology company specializing in rapid, whole genome sequencing-based diagnostics for infectious diseases, with a focus on modernizing diagnosis and treatment.
Company Overview
Day Zero Diagnostics focuses on developing rapid, whole genome sequencing-based diagnostics to modernize infectious disease diagnosis and treatment. The company is located at 250 Arsenal Place, Suite 320, Watertown, MA 02472. Day Zero Diagnostics partners with Oxford Nanopore to develop a same-day identification diagnostic system for clinical use.
Products and Services
Day Zero Diagnostics offers a rapid turnaround epiXact service using whole genome sequencing for infection control professionals. The company also developed technologies such as Blood2Bac for ultra-high enrichment of bacterial DNA from clinical samples. Their proprietary computational diagnostic algorithms, including Keynome ID and Keynome gAST, facilitate rapid pathogen identification and antimicrobial resistance profiling.
Funding and Awards
Day Zero Diagnostics has raised a total of $49 million in venture capital funding and over $18 million in non-dilutive funding as of 2023. The company has received numerous accolades, including Winner of the New England Region (2016), Finalist in MassChallenge HealthTech Digital Health Accelerator (2017), and Winner of the Disruptive Technology Award (2021).
Technological Innovations
Day Zero Diagnostics maintains a large-scale proprietary microbial database called MicrohmDB, which combines whole genome sequencing data with phenotypic resistance profiles. This database supports their diagnostic processes and innovations in the identification and profiling of pathogens. The company leverages advanced technology partnerships and in-house developed systems to streamline infectious disease diagnostics.